Zydus Cadila has received final approval from the US health regulator to market desvenlafaxine extended release tablets, used to treat depression.
Approval from the United States Food and Drug Administration (USFDA) is to market desvenlafaxine extended release tablets in the strengths of 50 mg and 100 mg, Zydus Cadila said in a BSE filing today.
The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya in Ahmedabad, it added.
The group now has more than 160 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.
Shares of Cadila Healthcare, the company’s listed entity, were today trading 1.41 per cent higher at Rs 498.30 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.